Chosa Oncology (CHOSA) Q4 2025 earnings summary

Executive summary

• Q4 2025 marked a transformative period with significant scientific, strategic, and financial progress, including new patent filings and clinical data supporting Platin-DRP® in predicting synergy between platinum therapy and immunotherapy.

• Expansion of Platin-DRP®'s clinical utility to predict overall survival in NSCLC patients, doubling its addressable market potential.

• Strengthened financial position through a directed share issue of approximately 7.3 MSEK after the reporting period.

Financial highlights

• Full-year result after financial items: -5,611 TSEK (2024: -4,772 TSEK); Q4 result: 699 TSEK (2024 Q4: 519 TSEK).

• Earnings per share after dilution: -0.07 SEK for the year (unchanged YoY); Q4: 0.009 SEK (2024 Q4: 0.007 SEK).

• Equity ratio at year-end: 82% (2024: 83%).

• Cash and cash equivalents at year-end: 1,791 TSEK (2024: 6,438 TSEK).

• Total assets: 20,252 TSEK (2024: 21,402 TSEK).

Outlook and guidance

• Ongoing focus on expanding partnerships with pharma and biotech for Platin-DRP® as a companion diagnostic.

• Continued clinical validation and regulatory preparations supported by new capital.

• Strategic aim to commercialize both Platin-DRP® and LiPlaCis through licensing, partnerships, and direct sales.